Alembic Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical products in India and internationally. It offers active pharmaceutical ingredients and formulations. The company also provides branded and generic formulations in various therapeutic areas, such as cardiology, gynecology, gastrology, ophthalmology, dermatology, nephrology/urology, orthopedics, anti-infective, cold and cough, and anti-diabetic. In addition, it exports its products. Alembic Pharmaceuticals Limited was founded in 1907 and is headquartered in Vadodara, India.
P/E ratio for Alembic Pharmaceuticals Limited (APLLTD.NS)
P/E ratio as of 2023: 32.20
According to Alembic Pharmaceuticals Limited's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 32.20. At the end of 2022 the company had a P/E ratio of 28.53.
P/E ratio history for Alembic Pharmaceuticals Limited from 2010 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | 32.20 |
| 2022 | 28.53 |
| 2021 | 27.98 |
| 2020 | 16.31 |
| 2019 | 12.15 |
| 2018 | 17.48 |
| 2017 | 24.86 |
| 2016 | 29.34 |
| 2015 | 15.68 |
| 2014 | 30.29 |
| 2013 | 22.82 |
| 2012 | 12.59 |
| 2011 | 6.99 |
| 2010 | 10.07 |